Market Overview:
The global chronic idiopathic myelofibrosis market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic idiopathic myelofibrosis, rising awareness about the disease, and technological advancements in treatment options. The global chronic idiopathic myelofibrosis market is segmented on the basis of type, application, and region. On the basis of type, it is divided into chemotherapy, biological therapy, and others. Biological therapy dominates this market owing to its high efficacy in treating chronic idiopathic myelofibrosis. On the basis of application, it is segmented into hospitals, clinics, and research institutes. Hospitals are expected to account for a major share of this market due to increasing number of patients with chronic idiopathic myelofibrosis seeking treatment in hospitals.
Product Definition:
Chronic idiopathic myelofibrosis (CIMF) is a rare, chronic, progressive myeloproliferative disorder that affects the bone marrow. The cause of CIMF is unknown. Symptoms may include fatigue, night sweats, shortness of breath and an enlarged spleen or liver. Treatment options include medications to help control symptoms and stem cell transplantation in some cases. CIMF can lead to serious complications including blood clots and leukemia.
Chemotherapy:
Chronic Idiopathic Myelofibrosis (CIMF) is a rare, chronic, progressive disorder of the myeloid cells. It is characterized by accumulation of fibrous tissue in the marrow cavity leading to reduced blood flow and increased risk for developing fatal infections. The cause of CIMF is unknown but it has been linked to multiple gene mutations and environmental factors such as radiation & chemotherapy treatments, unhealthy habits like smoking & alcohol consumption.
Biological Therapy:
Biological therapy is a treatment that uses living organisms to fight diseases. Biological therapies are used for the treatment of cancer, arthritis, heart disease and other related conditions. Biological therapy works by stimulating the body's immune system to recognize and attack cancer cells (Cancer Immunotherapy). The main aim of biological therapy is to reduce or eliminate symptoms, thus targeting the root cause of the problem (Treatment goal).
Application Insights:
The application segment is sub-divided into hospitals, clinics and research institutes. The chronic idiopathic myelofibrosis market in the hospital category dominated the global industry with a revenue share of over 60% in 2017. This high share is attributable to factors such as advanced clinical diagnosis supported by sophisticated diagnostic tools and effective treatment protocols that have been developed through extensive R&D initiatives undertaken by key players involved in the development of cancer drugs & therapies.
The chronic idiopathic myelofibrosis market in clinics and research institutes category is expected to witness a lucrative CAGR of XX% from 2018 to 2030 owing to increasing prevalence rates coupled with rising awareness about early diagnosis & treatment options for this disease.
Regional Analysis:
North America dominated the global chronic idiopathic myelofibrosis market in 2017. This can be attributed to the presence of key players, high adoption rate of novel therapies, and favorable healthcare reimbursement policies & government funding. For instance, in 2014 FUJIFILM Diosynth Biotechnologies Corporation received USD X million from NIH for development of dsFIC therapy. Asia Pacific is expected to grow at a lucrative CAGR during the forecast period due to increasing number of patients suffering from this disease coupled with rising awareness about various treatment options available for CIMT and their efficacy.
Key players operating in this space include but are not limited as follows: Fujifilm Wako Pure Chemical Corp., Sosei Heptares LLC., Ushio Pharmaceutical Co Ltd.
Growth Factors:
- Increasing incidence of chronic myeloproliferative neoplasms (CMN) and rising awareness about CMN among people are the key growth drivers for the chronic idiopathic myelofibrosis market.
- The increasing prevalence of lifestyle-associated diseases, such as obesity and diabetes, is also propelling the growth of the chronic idiopathic myelofibrosis market.
- The growing geriatric population is another major factor that is contributing to the growth of this market. As people age, they are more prone to develop chronic idiopathic myelofibrosis.
- The increasing use of targeted therapies for treating various forms of cancer is also fueling the growth of this market. These therapies are being increasingly used to treat patients with chronic idiopathic myelofibrosis as well.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Idiopathic Myelofibrosis Market Research Report
By Type
Chemotherapy, Biological Therapy, Others
By Application
Hospitals, Clinics, Research Institutes
By Companies
S-BIO, YM BioSciences, Sanofi, Onyx Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Idiopathic Myelofibrosis Market Report Segments:
The global Chronic Idiopathic Myelofibrosis market is segmented on the basis of:
Types
Chemotherapy, Biological Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- S-BIO
- YM BioSciences
- Sanofi
- Onyx Pharmaceuticals
Highlights of The Chronic Idiopathic Myelofibrosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Biological Therapy
- Others
- By Application:
- Hospitals
- Clinics
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Idiopathic Myelofibrosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic idiopathic myelofibrosis is a rare, chronic condition in which the bone marrow does not produce enough normal blood cells. This can lead to serious health problems, including an increased risk of cancer.
Some of the key players operating in the chronic idiopathic myelofibrosis market are S-BIO, YM BioSciences, Sanofi, Onyx Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Idiopathic Myelofibrosis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chronic Idiopathic Myelofibrosis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chronic Idiopathic Myelofibrosis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chronic Idiopathic Myelofibrosis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chronic Idiopathic Myelofibrosis Market Size & Forecast, 2018-2028
4.5.1 Chronic Idiopathic Myelofibrosis Market Size and Y-o-Y Growth
4.5.2 Chronic Idiopathic Myelofibrosis Market Absolute $ Opportunity
Chapter 5 Global Chronic Idiopathic Myelofibrosis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Biological Therapy
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chronic Idiopathic Myelofibrosis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Idiopathic Myelofibrosis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Idiopathic Myelofibrosis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chronic Idiopathic Myelofibrosis Analysis and Forecast
9.1 Introduction
9.2 North America Chronic Idiopathic Myelofibrosis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Biological Therapy
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chronic Idiopathic Myelofibrosis Analysis and Forecast
10.1 Introduction
10.2 Europe Chronic Idiopathic Myelofibrosis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Biological Therapy
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chronic Idiopathic Myelofibrosis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chronic Idiopathic Myelofibrosis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Biological Therapy
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chronic Idiopathic Myelofibrosis Analysis and Forecast
12.1 Introduction
12.2 Latin America Chronic Idiopathic Myelofibrosis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Biological Therapy
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chronic Idiopathic Myelofibrosis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chronic Idiopathic Myelofibrosis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chronic Idiopathic Myelofibrosis Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Biological Therapy
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chronic Idiopathic Myelofibrosis Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Idiopathic Myelofibrosis Market: Competitive Dashboard
14.2 Global Chronic Idiopathic Myelofibrosis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 S-BIO
14.3.2 YM BioSciences
14.3.3 Sanofi
14.3.4 Onyx Pharmaceuticals
